drugset / Trial / NCT00729664
Multiple Ascending Dose (MDX1105-01)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Collection of survival data, evaluation of PDL-1 expression in tumors, and evaluation of PD-L1 receptor occupancy in peripheral blood has been added.
Timeline
- Start
- 2009-02
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-936559 | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 10 mg/kg | Intravenous |
Indications
No indication recorded.